2seventy bio, Inc.

Third-quarter U.S. Abecma revenues as reported by BMS were $77 million, up 42% versus the prior quarter, according to management. The company recorded about $11 million of collaborative arrangement revenue in Q3. GAAP operating expenses declined by $10 million, or 24%, versus the prior quarter and by $140 million, or 52%, year to date versus the same period last year. Management guided 2024 U.S. Abecma revenue to approximately $240 million to $250 million, expects net cash spend of $40 million to $60 million for 2024, and said cash runway extends beyond 2027.

Chip Baird framed 2024 as a year of major simplification, saying the company sold its oncology and autoimmune R&D pipeline to Regeneron, sold its hemophilia A program to Novo Nordisk for $40 million, and reduced the company to 70 employees. His tone was upbeat but disciplined: he emphasized stronger Abecma growth, a more focused business, and continued work toward breakeven and strategic optionality. He also highlighted competitive positioning in third-line myeloma, saying Abecma has a differentiated safety profile and room to grow in a still underpenetrated market.

Vicki Eatwell emphasized that the quarter benefited from strong demand and a high fixed-cost operating model, which helped margins as sales improved. She said manufacturing success rates were north of 95%, supporting better profit-share economics, and reiterated that operating expenses should continue to decline in 2025 as the company streamlines costs. On liquidity, she reaffirmed net cash spend of $40 million to $60 million for 2024 and cash runway beyond 2027, while noting that breakeven is now viewed as closer to $300 million in total U.S. sales rather than the prior $400 million estimate.

Analysts focused on what is driving earlier-line CAR-T demand, how competitive dynamics are affecting Abecma, and whether the business is closer to breakeven. Management said demand has been a steady build rather than the bolus seen in the original launch, helped by more manufacturing capacity, more treatment sites, and greater awareness of CAR-T sequencing in third line. On seasonality, Chip Baird said fourth-quarter apheresis and infusion activity can soften around the holidays, but he said the underlying post-approval demand trend remains real and encouraging.